Sign In
Buy CDTX
$221.38
+0 (+0%)
At Close: Apr 07, 2026
Cidara Therapeutics to Participate in World Health Organization Meeting on H5N1 Influenza Preparedness and Response
08:00am, Wednesday, 19'th Mar 2025
SAN DIEGO, March 19, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunoth
Cidara Therapeutics Announces Two Presentations on CD388 in Influenza at International Conference on Antiviral Research (ICAR) 2025
08:00am, Tuesday, 18'th Mar 2025
SAN DIEGO, March 18, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunoth
Cidara Therapeutics Announces Publication of CD388 Preclinical Data in Nature Microbiology
06:00am, Monday, 17'th Mar 2025
Data highlights potential of CD388 as a potent, universal antiviral for influenza prevention regardless of immune status
Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results
04:35pm, Thursday, 06'th Mar 2025
SAN DIEGO, March 06, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (
Cidara Therapeutics Announces Appointment of Frank Karbe as Chief Financial Officer
04:15pm, Tuesday, 18'th Feb 2025
Industry veteran CFO Frank Karbe brings more than 25 years of leadership experience in the biopharma industry transitioning companies from R&D to commercialization Industry veteran CFO Frank Karbe bri
Bullish On Cidara Therapeutics As It Doubles Down On CD388 For Universal Flu Prevention
08:22am, Tuesday, 11'th Feb 2025
Cidara Therapeutics is leveraging its Cloudbreak platform to develop CD388 for universal influenza prophylaxis. Fortunately, they recently enrolled 5,000 subjects in its Phase 2b trial to assess CD388
Cidara Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference
04:05pm, Thursday, 30'th Jan 2025
SAN DIEGO, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunother
Cidara Therapeutics (CDTX) Just Flashed Golden Cross Signal: Do You Buy?
10:55am, Tuesday, 03'rd Dec 2024
Cidara Therapeutics, Inc. (CDTX) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, CDTX's 50-day simple moving average crossed
Cidara: Potential To Change Flu Prophylaxis Landscape With CD388
03:12pm, Thursday, 21'st Nov 2024
Results from phase 2b NAVIGATE study, using CD388 as a prophylaxis for Flu, expected to be released Q3 of 2025. CD388 offers broad influenza A and B coverage regardless of strain type and even effecti
Cidara Therapeutics Announces $105 Million Private Placement
08:30am, Thursday, 21'st Nov 2024
Financing led by new investor, Venrock Healthcare Capital Partners, with significant participation by new and existing life sciences-focused investors Financing led by new investor, Venrock Healthcare
Cidara Therapeutics to Participate in Evercore 7th Annual HealthCONx Conference
08:00am, Tuesday, 19'th Nov 2024
SAN DIEGO, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunother
Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
04:15pm, Thursday, 07'th Nov 2024
SAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (D
Cidara Therapeutics to Participate in Two Upcoming November Investor Conferences
08:00am, Thursday, 31'st Oct 2024
SAN DIEGO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunother
Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
04:30pm, Friday, 04'th Oct 2024
SAN DIEGO, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunothe
SAN DIEGO, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunoth
